Literature DB >> 15246268

H1 and H7 influenza haemagglutinin structures extend a structural classification of haemagglutinin subtypes.

R J Russell1, S J Gamblin, L F Haire, D J Stevens, B Xiao, Y Ha, J J Skehel.   

Abstract

Comparing the structures of H3, H5 and H9 subtype haemagglutinins, we deduced a structural basis for including all 15 influenza subtypes in four clades. H3, H5 and H9 represent three of these clades; we now report the structure of an H7 HA as a representative of the fourth clade. We confirm the structure of the turn at the N-terminus of the conserved central alpha-helix of HA2, and the combination of ionisable residues near the "fusion peptide" as clade-specific features. We compare the structures of three H1 HAs with H5 HA in the same clade, to refine our previous classification and we confirm the division of the clades into two groups of two. We also show the roles of carbohydrate side chains in the esterase-fusion domain boundaries in the formation of clade-specific structural markers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15246268     DOI: 10.1016/j.virol.2004.04.040

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  99 in total

Review 1.  Glycans as receptors for influenza pathogenesis.

Authors:  Karthik Viswanathan; Aarthi Chandrasekaran; Aravind Srinivasan; Rahul Raman; V Sasisekharan; Ram Sasisekharan
Journal:  Glycoconj J       Date:  2010-08-24       Impact factor: 2.916

2.  Structural analysis of the hemagglutinin from the recent 2013 H7N9 influenza virus.

Authors:  Hua Yang; Paul J Carney; Jessie C Chang; Julie M Villanueva; James Stevens
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

3.  Bovine lactoferrin-derived peptides as novel broad-spectrum inhibitors of influenza virus.

Authors:  Maria Grazia Ammendolia; Mariangela Agamennone; Agostina Pietrantoni; Fabio Lannutti; Rosa Anna Siciliano; Beatrice De Giulio; Carla Amici; Fabiana Superti
Journal:  Pathog Glob Health       Date:  2012-03       Impact factor: 2.894

4.  Accumulation of amino acid substitutions promotes irreversible structural changes in the hemagglutinin of human influenza AH3 virus during evolution.

Authors:  Katsuhisa Nakajima; Eri Nobusawa; Alexander Nagy; Setsuko Nakajima
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Infectivity studies of influenza virus hemagglutinin receptor binding site mutants in mice.

Authors:  Jeffrey Meisner; Kristy J Szretter; Konrad C Bradley; William A Langley; Zhu-Nan Li; Byeong-Jae Lee; Sudha Thoennes; Javier Martin; John J Skehel; Rupert J Russell; Jacqueline M Katz; David A Steinhauer
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

6.  Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge.

Authors:  Gayathri Bommakanti; Xianghan Lu; Michael P Citron; Tariq Ahmad Najar; Gwendolyn J Heidecker; Jan ter Meulen; Raghavan Varadarajan; Xiaoping Liang
Journal:  J Virol       Date:  2012-09-26       Impact factor: 5.103

Review 7.  Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme.

Authors:  Judith M White; Sue E Delos; Matthew Brecher; Kathryn Schornberg
Journal:  Crit Rev Biochem Mol Biol       Date:  2008 May-Jun       Impact factor: 8.250

8.  Identification of amino acid changes that may have been critical for the genesis of A(H7N9) influenza viruses.

Authors:  Gabriele Neumann; Catherine A Macken; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

9.  Structure, receptor binding, and antigenicity of influenza virus hemagglutinins from the 1957 H2N2 pandemic.

Authors:  Rui Xu; Ryan McBride; James C Paulson; Christopher F Basler; Ian A Wilson
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

Review 10.  H5N1 receptor specificity as a factor in pandemic risk.

Authors:  James C Paulson; Robert P de Vries
Journal:  Virus Res       Date:  2013-04-22       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.